Holen Sie sich die Stockscreener-App
0.79
3.08%
-0.0251
Schlusskurs vom Vortag:
$0.8151
Offen:
$0.8
24-Stunden-Volumen:
6.72M
Relative Volume:
1.01
Marktkapitalisierung:
$267.90M
Einnahmen:
$4.47M
Nettoeinkommen (Verlust:
$-71.67M
KGV:
-3.4081
EPS:
-0.2318
Netto-Cashflow:
$-59.58M
1W Leistung:
+1.24%
1M Leistung:
-21.00%
6M Leistung:
-52.69%
1J Leistung:
-48.37%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.782
$0.84
52-Wochen-Spanne:
$0.7803
$2.725
Ocugen Inc Stock (OCGN) Company Profile
Firmenname
Ocugen Inc
Sektor
Branche
Telefon
484-328-4701
Adresse
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, MRNA, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
0.79 | 267.90M | 4.47M | -71.67M | -59.58M | -0.2318 |
VRTX
Vertex Pharmaceuticals Inc
|
535.17 | 135.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
819.09 | 84.33B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
202.63 | 80.90B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
875.76 | 55.07B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
382.27 | 43.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-17 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-03-11 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-15 | Eingeleitet | Maxim Group | Buy |
| 2023-03-01 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | Eingeleitet | Mizuho | Buy |
| 2022-06-15 | Fortgesetzt | ROTH Capital | Buy |
| 2022-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-07-26 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-06-11 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
Alle ansehen
Ocugen Inc Aktie (OCGN) Neueste Nachrichten
Ocugen (NasdaqCM:OCGN) Stock Forecast & Analyst Predictions - Simply Wall Street
An officer proposes selling 525,991 Ocugen (OCGN) shares through Merrill Lynch. - Stock Titan
Ocugen Stockholders Approve Meeting Adjournment for Share Increase - The Globe and Mail
Ocugen CEO Musunuri sells $589,109 in shares, priced $1.06-$1.31 By Investing.com - Investing.com Australia
Ocugen CEO Musunuri sells $589,109 in shares, priced $1.06-$1.31 By Investing.com - Investing.com Canada
Ocugen CEO Musunuri sells $589,109 in shares, priced $1.06-$1.31 - investing.com
Ocugen: Q3 Data Catalyst In Stargardt Disease Feels Critical (NASDAQ:OCGN) - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Axsome Therapeutics (AXSM) and Ocugen (OCGN) - The Globe and Mail
Ocugen CEO Musunuri sells $589,109 in shares, priced $1.06-$1.31 - Investing.com
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
OCGN Stock Slips As Traders Focus On Weak Financials - StocksToTrade
OCGN Stock Slips As Weak Financials Weigh On Momentum - timothysykes.com
Ocugen: My Hold Rating Continued On OCU410ST Advancement And Upcoming Catalysts (OCGN) - Seeking Alpha
What's Happening With Ocugen Stock Thursday? - TradingView
H.C. Wainwright cuts Ocugen stock price target to $9.50 on trial delay - Investing.com India
H.C. Wainwright cuts Ocugen stock price target to $9.50 on trial delay - Investing.com Canada
H.C. Wainwright cuts Ocugen stock price target to $9.50 on trial delay - Investing.com UK
H.C. Wainwright cuts Ocugen stock price target to $9.50 on trial delay - Investing.com
OCGN Maintains Buy by HC Wainwright & Co. -- Price Target Lowered to $9.50 - GuruFocus
H.C. Wainwright cuts Ocugen stock price target to $9.50 on trial delay By Investing.com - Investing.com South Africa
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
An Ocugen (NASDAQ: OCGN) insider plans a stock sale; the exact size is detailed in an SEC notice - Stock Titan
OCGN Looks 32.9% Overvalued on GF Value™ Amid Phase 2/3 Trial Se - GuruFocus
Ocugen slips after Stargardt disease trial data (OCGN:NASDAQ) - Seeking Alpha
OCGN Stock Slides As Traders Focus On Cash Burn And Key Support - timothysykes.com
Ocugen doses first patient in phase 3 GA gene therapy trial - Glance by Eyes On Eyecare
Ocugen Announces US$40 Million Registered Direct Offering Priced at $2.00 Per Share - Minichart
Ocugen to Share Ophthalmic Gene Therapy Progress - TipRanks
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Doses First Patient in Phase 3 Trial of OCU410 for GA - cgtlive.com
Malvern’s Ocugen Starts Pivotal Trial for Eye Gene Therapy - MyChesCo
Ocugen stock edges higher as investors watch recent quarterly figures - AD HOC NEWS
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen (NASDAQ:OCGN) Penny Stock Nears Major Gene Therapy Catalyst - Kalkine Media
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy - Yahoo Finance
Ocugen Doses First Patient in Global Phase 3 Trial of OCU410 for Geographic Atrophy - Eyewire+
Ocugen Eases on Tests - Baystreet.ca
Ocugen doses first patient in phase 3 gene therapy trial for GA - Investing.com Canada
OCGN Looks 61.0% Overvalued on GF Value™ - GuruFocus
Ocugen doses first patient in phase 3 gene therapy trial for GA - Investing.com Australia
Ocugen doses first patient in phase 3 gene therapy trial for GA - Investing.com Nigeria
Ocugen doses first patient in phase 3 gene therapy trial for GA - Investing.com
Ocugen Doses First Patient in Global Phase 3 ArMaDa3 Trial of OCU410 for Geographic Atrophy and Receives FDA RMAT Designation - Quiver Quantitative
Ocugen doses first patient in phase 3 gene therapy trial for GA - Investing.com UK
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Ocugen, Inc.
Ocugen Doses First Patient in OCU410 Phase 3 Trial | OCGN Stock News - Stock Titan
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Yahoo Finance
Ocugen Eases on Tests - Baystreet.ca
Malvern Biotech Ocugen to Present New Eye Gene Therapy Data - MyChesCo
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Finanzdaten der Ocugen Inc-Aktie (OCGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ocugen Inc-Aktie (OCGN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Shankar Musunuri | Officer |
Oct 09 '26 |
Proposed Sale |
0.95 |
525,991 |
497,965 |
0 |
| Musunuri Shankar | Chief Executive Officer |
Oct 09 '26 |
Sale |
0.95 |
57,264 |
54,401 |
1,030,771 |
| Shankar Musunuri | Officer |
Sep 09 '26 |
Proposed Sale |
1.12 |
525,991 |
589,741 |
0 |
| Musunuri Shankar | Chief Executive Officer |
Sep 09 '26 |
Sale |
1.12 |
57,264 |
64,136 |
1,088,035 |
| Musunuri Shankar | Chief Executive Officer |
Sep 09 '26 |
Sale |
1.12 |
468,727 |
524,974 |
4,487,197 |
| Johnson-Greene Treerita Essali | Chief Financial Officer |
Jun 15 '26 |
Buy |
1.23 |
21,000 |
25,830 |
521,000 |
| Zhang Junge | Director |
Apr 01 '26 |
Option Exercise |
0.79 |
194,134 |
154,303 |
1,359,316 |
0.68%
3.98%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):